Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: Systematic review;Eficacia y seguridad de la inyección intravítrea de bevacizumab en el tratamiento del glaucoma neovascular: Revisión sistemática

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 83, Issue 10, 2008, Pages 579-587

  Martínez Carpio, Pedro A ^a,b,c   Bonafonte Marquez E ^a   Heredia Garcia C D ^a   Bonafonte Royo, S ^a  

^a Centro de Oftalmología Bonafonte Barcelona   (Spain)

^b GIRSANE CAR Sant Cugat del Vallès   (Spain)

^c IMC Investiláser ^*  (Spain)

Author keywords

Avastin; Bevacizumab; Growth factors; Intravitreal injection; Laser photocoagulation; Neovascular glaucoma; Rubeosis iridis; Systematic review

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

HUMAN; INJECTION; NEOVASCULAR GLAUCOMA; REVIEW; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; GLAUCOMA, NEOVASCULAR; HUMANS; INJECTIONS; VITREOUS BODY;

EID: 58649118826     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Martínez-Carpio PA, Mur C, Rosel P, Navarro MA. Constitutive and regulated secretion of epidermal growth factor and transforming growth factor-beta1 in MDA-MB-231 cell line in 11-day cultures. Cell Signal 1999; 11: 753-757.
2. Martínez-Carpio PA, Mur C, Fernández-Montolí ME, Ramon JM, Rosel P, Navarro MA. Secretion and dual regulation between epidermal growth factor and transforming growth factor-beta1 in MDA-MB-231 cell line in 42 hour-long cultures. Cancer Lett 1999; 147: 25-29.
3. Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, Weinstein IB. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2002; 2: 350-359.
4. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmon HP, Bouchier-Hayes DJ. TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997; 4: 621-627.
5. Valente S, Souto B, Balter H, Welling MM, Román E, Robles A, et al. Interaction of a monoclonal antibody against hEGF with a receptor site for EGF. Nucl Med Biol 1999; 26: 937-942.
6. Liss C, Fekete MJ, Hasina R, Lam CD, Lingen MW. Paracrine angiogenic loop between head-and-neck squamouscell carcinomas and macrophages. Int J Cancer 2001; 93: 781-785.
7. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599.
8. Rosenfeld P. An update on bevacizumab. Rev Ophthalmol 2005; 12:12.
9. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41: 614-625.
10. Bonafonte S, Arévalo F, García RA. Neovascularizació n del iris y glaucoma neovascular. En: Bonafonte S, García ChA. Retinopatía Diabética. II Ed. Madrid: Elsevier España, 2006.
11. Spratt A, Ogunbowale L, Franks W. Bevacizumab: a compassionate way of doing business? Eye 2007; 21: 890-891.
12. Dickersin K, Scherer R, Lefevre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309: 1286-1291.
13. Helmer D, Savoie I, Green C, Kazanjian A. Evidence-based practice: extending the search to find material for the systematic review. Bull Med Libr Assoc 2001; 89: 346-352.
14. Soualmia LF, Dahamna B, Thirion B, Darmoni SJ. Strategies for health information retrieval. Stud Health Technol Inform 2006; 124: 595-600.
15. Darmoni SJ, Thirion B, Leroyt JP, Douyère M, Lacoste B, Godard C, et al. A search tool based on "encapsulated" MeSH thesaurus to retrieve quality health resources on the internet. Med Inform Internet Med 2001; 26: 165-178.
16. Shahar E. A popperian perspective of the term «evidence-based medicine». J Eval Clin Pract 1997; 3: 109-116.
17. Osborn J. Observation, Sherlock Holmes, and Evidence Based Medicine. Med Secoli 2002; 14: 515-527.
18. Gheith ME, Siam GA, de Barros DS, Garg SJ, Moster MR. Role of intravitreal bevacizumab in neovascular glaucoma. J Ocul Pharmacol Ther 2007; 23: 487-491.
19. Kelkar AS, Kelkar SB, Kelkar JA, Nagpal M, Patil SP. The use of intravitreal bevacizumab in neovascular glaucoma: a case report. Bull Soc Belge Ophthamol 2007; 303: 43-45.
20. Yazdani S, Hendi K, Pakravan M. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007; 16: 437-439.
21. Chilov MN, Grigg JR, Playfair TJ. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 2007; 35: 494-496.
22. Batioglu F, Astam N, Ozmert E. Rapid improvement of retinal and iris neovascularisation after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. Int Ophthalmol 2008; 28: 59-61.
23. Vatavuk Z, Bencic G, Mandic Z. Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur J Ophthalmol 2007; 17: 269-271.
24. Jonas JB, Spandau UH, Schlichtenbrede F. Intravitreal bevacizumab for filtering surgery. Ophthalmic Res 2007; 39: 121-122.
25. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolg S, Sarra GM. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006; 142: 1054-1056.
26. Mason JO 3rd, Albert MA Jr, Mays A, Vail R. Regression of neovascular iris vessels by intravitreal injection of bavacizumab. Retina 2006; 26: 839-841.
27. Silva Paula J, Jorge R, Alves Costa R. Rodrigues Mde L, Scoutt IU. Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 2006; 84: 556-557.
28. Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU, et al. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142: 158-160.
29. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006; 37: 144-146.
30. Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina 2006; 26: 354-356.
31. Avery RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 352-354.
32. Oshima Y, Sakaguchi H, Gomi F, Tano Y. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 155-158.
33. Al-Aswad L. Another role for Avastin? Neovascular glaucoma. Rev Ophthalmol 2006; 13: 6.
34. Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008; 115: 1571-1580.
35. Ehlers JP, Spirn MJ, Lam A, Sivalingam A, Samuel MA, Tasman W. Combination intravitreal bevacizumab/panretinal photocoagulation versus panretinal photocoagulation alone in the treatment of neovascular glaucoma. Retina 2008; 28: 696-702.
36. Chalam KV, Gupta SK, Grover S, Brar VS, Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol 2008; 18: 255-262.
37. Kitnarong N, Chindasub P, Metheetrairut A. Surgical outcome of intraviteal bevacizumab and filtration surgery in neovascular glaucoma. Adv Ther 2008; 25: 438-443.
38. Cheng JY, Wong DW, Ang CL. Intraocular avastin (bevacizumab) for neovascularization of the iris and neovascular glaucoma. Ann Acad Med Singapore 2008; 37: 72-74.
39. Cornish KS, Ramamurthi S, Saidkasimova S, Ramaesh K. Intravitreal bevacizumab and augmented trabeculectomy for neovascular glaucoma in young diabetic patients. Eye 2008; 2: doi:10.138/eye.2008.113.
40. Sothornwit N. Intravitreal bevacizumab for ahmed glaucoma valve implantation in neovascular glaucoma: a case report. J Med Assoc Thail 2008; 91: S162-S165.
41. Bianciotto C, Shields CL, Kang B, Shields JA. Treatment of iris melanoma and secondary neovascular glaucoma using bevacizumab and plaque radiotherapy. Arch Ophthalmol 2008; 126: 578-579.
42. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-1705.
43. Groover S, Gupta SK, Sharma RK, Brar VS, Chalam KV. Intracameral Bevacizumab Effectively Reduces Aqueous VEGF Levels in Neovascular Glaucoma. Br J Ophthalmol 2008; 10 [Epub ahead of print].
44. Martínez-Carpio PA, Navarro Moreno MA. Growth factors, cell damage, cyclin-dependent kinases and their inhibitors: relevance in molecular pathology of human cancer. Med Clin (Barc) 2003; 120: 265-271.
45. Tamm ER, Fuchshofer R. What increases outflow resistance in primary open-angle glaucoma? Surv Ophthalmol 2007; 52: S101-S104.
46. Iyengar L, Patkunanathan B, Lynch OT, McAvoy JW, Rasko JE, Lovicu FJ. Aqueous humor and growth factor-induced lens cell proliferation is dependent on MAPK/ERK1/2 and Akt/p13-K signalling. Exp Eye Res 2006; 83: 667-678.
47. Tu KL, Kaye SB, Sidaras G, Taylor W, Shenkin A. Effect of intraocular surgery and ketamine on aqueous and serum cytokines. Mol Vis 2007; 13: 1130-1137.
48. Vela JI, Galán A, Fernández E, Romera M, Torres JJ. Uveítis anterior y artritis idiopática juvenil. Arch Soc Esp Oftalmol 2003; 78: 561-565.
49. Simón G. Trabeculoplastia con dos tipos de láser en gato, monos y humano: estudio morfológico con microscopía electrónica de barrido. Arch Soc Esp Oftalmol 2006; 81: 527-536.